Describe and discuss the epidemiology, genetic basis ,pathogenesis clinical evolution and course of common causes of heart disease including: rheumatic/ valvular, ischemic, hypertrophic inflammatory.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Here is a detailed, integrated discussion of each major category of heart disease, drawing from Harrison's Principles of Internal Medicine 22E, Braunwald's Heart Disease, Robbins & Kumar Basic Pathology, and Goldman-Cecil Medicine.

Common Causes of Heart Disease: Epidemiology, Genetics, Pathogenesis, and Clinical Course

1. Rheumatic / Valvular Heart Disease

Epidemiology

Rheumatic heart disease (RHD) is the most common acquired cardiac condition in children and young adults worldwide. It remains a major public health problem in low- and middle-income countries (sub-Saharan Africa, South/Southeast Asia, Pacific Islands, and parts of Latin America), where it accounts for 40% of all cardiovascular admissions. The annual incidence of acute rheumatic fever (ARF) in high-burden settings exceeds 50 per 100,000 children aged 5-14. In developed countries, RHD is now rare following improvements in living standards, antibiotic availability, and streptococcal control. Globally, approximately 40 million people live with RHD, and it causes around 300,000 deaths per year. The disease disproportionately affects populations living in poverty due to overcrowding and inadequate access to healthcare.

Calcific (non-rheumatic) aortic stenosis is the dominant form of valvular disease in developed countries, typically presenting in the 7th-8th decade; it shares risk factors with coronary artery disease (hypertension, hyperlipidaemia) and results from active inflammation rather than passive degeneration.

Genetic Basis

Susceptibility to ARF is partially inherited. Approximately 3-6% of any given population is susceptible regardless of geography. Monozygotic twin concordance is 44% vs. 12% in dizygotic twins; heritability is estimated at ~60%. Genome-wide association studies have identified associations with:

The immunoglobulin heavy chain locus (specifically the IGHV4-61*02 allele)
Complement factor H genes
HLA class II alleles (HLA-DQ A and B subtypes) - both susceptibility and protective variants exist
Polymorphisms in TNF and mannose-binding lectin genes

These associations vary by population, suggesting a complex multigenic architecture. No single "rheumatic fever gene" has been identified.

Pathogenesis

ARF follows group A streptococcal (GAS, Streptococcus pyogenes) infection of the throat - and increasingly, evidence implicates skin infection as well. Certain M-protein serotypes (historically types 1, 3, 5, 6, 14, 18, 19, 24, 27, 29) are considered rheumatogenic, though many more serotypes are now known to be capable.

The central mechanism is molecular mimicry: antibodies raised against streptococcal M-protein antigens cross-react with host cardiac proteins including myosin, actin, tropomyosin, laminin, and keratin. This leads to:

Antigen-presenting cells process GAS antigens and present them to T cells
Cross-reactive antibodies bind endothelial cells on heart valves, activating VCAM-1
Activated lymphocytes are recruited; complement-mediated lysis of endothelial cells releases host peptides (laminin, keratin, tropomyosin)
Cross-reactive T cells invade the heart, amplifying damage via epitope spreading
Aschoff bodies (pathognomonic granulomatous lesions with Anitschkow cells) form in the myocardium and valves

The mitral valve is almost universally involved; the aortic valve is involved in a significant minority. Isolated aortic involvement without mitral disease is rare. Repeated episodes of streptococcal infection drive progressive valvular scarring, leaflet thickening, calcification, and fusion of commissures, converting the initial regurgitant lesion into stenosis over years to decades.

Harrison's Principles of Internal Medicine 22E, pp. 2897-2900

Clinical Evolution and Course

Latent period: ~3 weeks (range 1-5 weeks) between GAS infection and ARF onset; chorea and indolent carditis may follow latencies up to 6 months
Acute ARF: polyarthritis (60-75%), carditis (50-75%), Sydenham's chorea (up to 30% in some populations), erythema marginatum, subcutaneous nodules
Carditis: up to 75% of ARF cases develop RHD. Early lesion = mitral regurgitation ± aortic regurgitation. Later (years to decades of recurrent episodes): leaflet thickening, scarring, calcification → mitral stenosis (hallmark of chronic RHD), also aortic stenosis/regurgitation
Chronic RHD: patients are often asymptomatic for many years. When significant obstruction or regurgitation develops, symptoms include dyspnoea, fatigue, palpitations (atrial fibrillation is common), and eventually heart failure
Complications: atrial fibrillation (from left atrial dilatation in mitral stenosis), systemic embolism, infective endocarditis, pulmonary hypertension, and right heart failure
Prevention: secondary prophylaxis with long-term penicillin (benzathine penicillin G, every 3-4 weeks) is the cornerstone of management to prevent recurrences and halt valvular progression

2. Ischemic Heart Disease (IHD)

Epidemiology

IHD (synonymous with coronary artery disease, CAD) is the leading cause of death globally, responsible for approximately 9 million deaths per year. It accounts for the largest share of cardiovascular mortality in high-income countries, though rates have declined substantially since the 1970s due to risk factor modification and revascularisation therapies. In low- and middle-income countries, the burden is rising. Men are affected earlier than women; postmenopausal women approach equivalent risk. Risk factors are well established: cigarette smoking, hypertension, dyslipidaemia (raised LDL, low HDL), diabetes mellitus, obesity, physical inactivity, family history, and age.

The spectrum of IHD includes:

Chronic stable angina (chronic coronary syndrome)
Acute coronary syndromes (ACS): unstable angina, NSTEMI, and STEMI
Ischaemic cardiomyopathy / heart failure with reduced ejection fraction (HFrEF)
Sudden cardiac death

Genetic Basis

IHD is polygenic. Genome-wide association studies have identified over 160 independent genetic loci associated with CAD risk. Key genetic contributors include:

9p21.3 locus (near CDKN2A/B): the strongest individual locus, associated with ~30% increased relative risk per allele; mechanism involves regulation of cell proliferation in the vessel wall
LPA gene variants: elevated lipoprotein(a) levels confer substantial additional risk
PCSK9 variants: loss-of-function variants markedly lower LDL and reduce CAD risk
LDLR, APOB, APOE: variants in lipoprotein handling genes; familial hypercholesterolaemia (FH) - caused by LDLR mutations (most common), APOB mutations, or PCSK9 gain-of-function variants - produces very high LDL and premature IHD
Heritability of CAD is approximately 40-60%; polygenic risk scores incorporating thousands of SNPs are increasingly used to identify high-risk individuals

Monogenic causes (FH, familial combined hyperlipidaemia) account for a minority but produce very early, aggressive disease.

Pathogenesis

The dominant mechanism is atherosclerosis:

Endothelial injury (from hypertension, oxidised LDL, smoking, haemodynamic shear stress): increases endothelial permeability, upregulates adhesion molecules (VCAM-1, ICAM-1)
Lipid accumulation: LDL enters the subintimal space, undergoes oxidative modification; oxidised LDL is pro-inflammatory
Monocyte recruitment: monocytes adhere to activated endothelium, transmigrate, and differentiate into macrophages, which take up modified LDL via scavenger receptors to become foam cells (early fatty streak)
Smooth muscle cell (SMC) migration: SMCs migrate from media to intima, proliferate, secrete extracellular matrix, forming the fibrous cap
Plaque progression: the plaque develops a necrotic lipid core (dead foam cells) covered by fibrous cap; the fibrous cap is thin in "vulnerable plaques"
Plaque rupture or erosion: triggers thrombus formation on the exposed lipid core or denuded endothelium; this is the precipitating event in most ACS

In stable angina, fixed plaques cause flow-limiting stenosis (typically >70% of luminal diameter); ischaemia occurs predictably with exertion when demand exceeds supply.

In ACS, vulnerable plaque rupture causes superimposed thrombosis; partial occlusion → unstable angina/NSTEMI; complete occlusion → STEMI.

Ischaemia beyond 20-40 minutes causes irreversible myocyte necrosis (infarction), progressing as a wavefront from subendocardium to epicardium.

Clinical Evolution and Course

Asymptomatic subclinical atherosclerosis: fatty streaks can appear in the aorta in childhood; significant plaques develop over decades
Stable angina: effort-induced chest pain (substernal, pressurelike, radiating to arm/jaw), relieved by rest or nitroglycerin; represents fixed stenosis with preserved resting flow
ACS spectrum: sudden onset or rapidly worsening angina at rest; STEMI presents with ST elevation on ECG and requires urgent reperfusion (PCI or thrombolysis); NSTEMI has troponin elevation without ST elevation
Post-MI remodelling: surviving myocardium undergoes compensatory hypertrophy; infarcted zone undergoes fibrotic scarring; progressive left ventricular dilation may lead to ischaemic cardiomyopathy (HFrEF) over months to years
Long-term course: determined by extent of left ventricular dysfunction, presence of residual ischaemia, arrhythmia risk, and comorbidities. Ejection fraction <35-40% carries substantial mortality risk and may warrant ICD implantation
Complications: arrhythmias (VF causing sudden cardiac death - especially in first 24-48 hours post-MI), papillary muscle rupture (acute mitral regurgitation), ventricular septal rupture, free wall rupture, Dressler syndrome (post-infarction pericarditis), mural thrombus and embolism

3. Hypertrophic Cardiomyopathy (HCM)

Epidemiology

HCM is the most common inherited heart disease, with a prevalence of approximately 1 in 500 in the general adult population. It affects all ethnic groups and both sexes equally, though clinical presentation and prognosis may differ. HCM is the most common identifiable cause of sudden cardiac death (SCD) in athletes and young people under 35 years of age in the United States and Europe. It accounts for roughly 1 in 3 sudden cardiac deaths in young athletes and is responsible for significant SCD in the general young adult population.

Genetic Basis

HCM is a sarcomeric protein disease inherited in an autosomal dominant pattern with variable penetrance and expressivity. More than 400 causative mutations across at least 9 sarcomeric protein genes have been identified. All known mutations share a unifying feature: they are gain-of-function mutations that enhance myofilament activity. This leads to myocyte hypercontractility, increased energy consumption, and net negative energy balance in the myocardium.

The three most frequently mutated genes account for 70-80% of genetic HCM:

Gene	Protein	% of Cases
MYH7	Beta-myosin heavy chain	~35-40%
MYBPC3	Myosin-binding protein C	~25-30%
TNNT2	Troponin T	~5%

Other genes include TNNI3 (troponin I), TPM1 (alpha-tropomyosin), MYL2, MYL3, ACTC1, and TNNC1. Notably, some mutations in MYH7 also cause dilated cardiomyopathy (DCM), but in DCM these are loss-of-function mutations - the opposite of HCM.

Approximately 5-10% of cases may have digenic inheritance (mutations in two sarcomeric genes), which tends to produce more severe phenotype.

Robbins & Kumar Basic Pathology, p. 373-374

Pathogenesis

Gain-of-function sarcomeric mutations produce myocyte hypercontractility and impaired relaxation. The result is:

Diastolic dysfunction: the stiffened, hypercontractile myocardium fails to fully relax during diastole → impaired ventricular filling → raised end-diastolic pressure → pulmonary venous hypertension
Asymmetric septal hypertrophy (ASH): present in 90% of cases - disproportionate thickening of the ventricular septum relative to the free wall compresses the left ventricular cavity into a "banana-like" shape on cross-section
Left ventricular outflow tract (LVOT) obstruction: systolic anterior motion (SAM) of the anterior mitral leaflet contacts the hypertrophied septum during systole in approximately one-third of patients, causing dynamic obstruction; this is the substrate for the characteristic harsh systolic ejection murmur (which increases with Valsalva and decreases with squatting)
Myocardial ischaemia: massive hypertrophy + high LV pressures + reduced coronary reserve (insufficient capillary density for the hypertrophied mass) → angina even without epicardial CAD
Histology: the cardinal histologic triad is marked myocyte hypertrophy, haphazard myocyte and myofiber disarray, and interstitial fibrosis - disarray being pathognomonic and likely the substrate for arrhythmias and SCD

Clinical Evolution and Course

Presentation: commonly manifests during postpubertal growth spurt; can present at any age; many patients remain asymptomatic for decades and are diagnosed incidentally on echocardiography or during family screening
Symptoms: exertional dyspnoea (most common), angina (from myocardial ischaemia), presyncope/syncope (from obstruction or arrhythmia), and palpitations (from AF or ventricular arrhythmias)
SCD risk: the most feared complication; risk factors include: prior cardiac arrest, sustained VT, family history of SCD, massive hypertrophy (septal thickness ≥30 mm), unexplained syncope, abnormal blood pressure response to exercise, and non-sustained VT on Holter. ICD implantation is recommended in those with high SCD risk
Atrial fibrillation: occurs in up to 25% of patients with HCM; causes significant haemodynamic deterioration and embolic risk; anticoagulation is warranted
End-stage HCM: ~5-10% of patients develop a "burnt-out" or dilated phase with ventricular dilation, systolic dysfunction, and progressive heart failure, often requiring advanced therapies (transplantation or LVAD)
Medical management: negative inotropes/dromotropes (beta-blockers, verapamil, diltiazem) to promote ventricular relaxation and reduce outflow obstruction; disopyramide added for obstruction-related symptoms; mavacamten (cardiac myosin inhibitor) is a newer targeted therapy
Septal reduction therapy: surgical myectomy (Morrow procedure) or alcohol septal ablation for drug-refractory symptomatic obstruction

4. Inflammatory Heart Disease (Myocarditis and Pericarditis)

Epidemiology

Myocarditis: The 2019 Global Burden of Disease study estimated a global prevalence of approximately 712,780 cases (prevalence rate ~9.21 per 100,000), up from ~8.04/100,000 in 1990. An estimated 32,449 deaths were attributable to myocarditis in 2019. The death rate is highest in infancy, then rises again after age 15 with a male predominance. Rates are highest in parts of Southeast Asia, East Asia, Oceania, Central Europe, Eastern Europe, and Central Asia. Myocarditis is responsible for SCD in approximately 2% of infants, 5% of children, and 5-14% of young athletes. It contributes substantially to newly diagnosed dilated cardiomyopathy.

Pericarditis: Acute pericarditis is more common, estimated to account for approximately 5% of emergency department visits for non-ischaemic chest pain. The majority of cases in developed countries are viral or idiopathic.

Genetic Basis

Inflammatory heart disease does not have a primary genetic basis in the way cardiomyopathies do, but host genetic factors modulate susceptibility and severity:

HLA alleles influence immune response to viral antigens and autoantigen presentation
In immune checkpoint inhibitor (ICI)-associated myocarditis, immune checkpoint gene variants (PD-1, CTLA-4 pathway) modulate risk
In Chagas disease (T. cruzi), HLA and cytokine gene polymorphisms influence who develops chronic cardiomyopathy vs. remains in the indeterminate phase
Genetic cardiomyopathies (e.g., DCM-associated mutations) can lower the threshold for clinically apparent myocarditis following viral infection

Pathogenesis of Myocarditis

Causes span the entire microbial world and include autoimmune/toxic triggers. In the United States and Western Europe, viruses predominate:

Most common: Parvovirus B19 (infects cardiac endothelial cells, not myocytes), human herpesvirus 6 (HHV-6)
Classic: Coxsackievirus B and other enteroviruses (infect cardiac myocytes via the CAR receptor - coxsackievirus-adenovirus receptor; also uses DAF/CD55 as co-receptor)
Others: CMV, HIV, influenza, adenovirus, SARS-CoV-2

The pathogenesis proceeds through three phases:

Phase 1 - Viral infection and replication: Virus enters the host through the respiratory or GI tract, undergoes primary replication in organs such as liver, spleen, and pancreas, then reaches the heart via blood or lymphatics. Coxsackievirus B binds the CAR receptor at the intercalated disc, is internalised, replicates, and lyses myocytes. Viral proteases (2A and 3C) cleave dystrophin, disrupting the cytoskeletal scaffold and impairing myocyte structural integrity.

Phase 2 - Immunologic response:

Innate immunity: pattern recognition receptors (TLRs) detect viral PAMPs; interferons are produced; NK cells are recruited
Adaptive immunity: T cell (especially cytotoxic CD8+) infiltrates develop; in most cases this is protective and clears the virus; B cells produce neutralising antibodies
Immunopathology: when the immune response is excessive or misdirected, T cells and antibodies target self-antigens (e.g., cardiac myosin heavy chain) - autoimmune myocarditis ensues even after viral clearance
Dallas criteria (histologic diagnosis): active myocarditis = inflammatory infiltrate with myocyte necrosis or damage not consistent with ischaemia

Phase 3 - Chronic remodelling: If the inflammatory response is not adequately resolved, persistent cardiac inflammation drives fibrosis, ventricular dilation, and systolic dysfunction, i.e., the development of dilated cardiomyopathy (DCM). Viral genomes may persist in myocardium and be detected on endomyocardial biopsy even without active inflammation.

Non-viral causes:

Trypanosoma cruzi (Chagas disease): endemic in Latin America; ~300,000 infected individuals live in the US; ~10% die during acute attack; others enter a silent indeterminate phase; 10-20 years later, chronic immune-mediated cardiomyopathy with heart failure and arrhythmia develops in ~30%
Borrelia burgdorferi (Lyme disease): myocarditis in ~5% of Lyme disease cases; manifests mainly as self-limited conduction system disease (AV block), often requiring temporary pacing
Toxoplasma gondii: particularly in immunocompromised hosts
mRNA COVID-19 vaccination: rare post-vaccination myocarditis, especially in male adolescents/young adults after the 2nd dose; most cases recover uneventfully
Immune checkpoint inhibitors (ICIs): incidence 0.3-1%; can cause fulminant myocarditis; treated with high-dose corticosteroids ± T-cell inhibitors (alemtuzumab, abatacept)
Drug hypersensitivity myocarditis: eosinophilic infiltrate; typically mild; rarely fatal
Autoimmune diseases: SLE, polymyositis, sarcoidosis (granulomatous myocarditis)
Braunwald's Heart Disease, pp. 699-735; Robbins & Kumar Basic Pathology, p. 375

Clinical Evolution and Course

Myocarditis:

Acute presentation: highly variable - ranges from subclinical (incidental troponin elevation) to fulminant heart failure, cardiogenic shock, or life-threatening arrhythmia
Classic presentation: young patient with flu-like prodrome followed days to weeks later by chest pain (pericarditic or pleuritic), dyspnoea, palpitations, and signs of heart failure
ECG: may show ST changes (diffuse or focal), T-wave inversions, arrhythmias, or conduction block
Cardiac MRI: most sensitive non-invasive test; shows myocardial oedema (T2-weighted hyperintensity) and late gadolinium enhancement (LGE) reflecting fibrosis/inflammation
Endomyocardial biopsy (EMB): remains the histologic gold standard but has sampling error; recommended in haemodynamically unstable patients with suspected fulminant myocarditis
Most common outcome: self-limited with full recovery in 4-6 weeks when supportive care is provided
Poor outcome predictors: fulminant presentation, ventricular dysfunction, giant cell myocarditis (requires aggressive immunosuppression), eosinophilic myocarditis
Chronic outcome: 10-30% develop persistent ventricular dysfunction leading to DCM; these patients require standard heart failure therapy (ACE inhibitors, beta-blockers, diuretics, aldosterone antagonists); advanced heart failure may require LVAD or transplantation
Giant cell myocarditis: rare, rapidly progressive, fatal without immunosuppression or transplantation; associated with autoimmune conditions and thymoma

Pericarditis:

Most commonly viral/idiopathic; also seen in ARF, post-MI (Dressler syndrome), uraemia, autoimmune disease, malignancy, post-cardiac surgery
Presents with sharp pleuritic chest pain (worse supine, relieved sitting forward), pericardial friction rub, diffuse saddle-shaped ST elevation on ECG
Treatment: NSAIDs + colchicine (reduces recurrence); corticosteroids reserved for non-responders or specific causes (autoimmune, uraemic)
Complications: pericardial effusion, cardiac tamponade, constrictive pericarditis (fibrotic restriction of diastolic filling, usually after recurrent/prolonged inflammation)

Summary Comparison Table

Feature	Rheumatic/Valvular	Ischemic (CAD)	Hypertrophic (HCM)	Inflammatory
Epidemiology	Prevalent in LMICs; rare in developed world	Leading cause of death globally	1:500 general population	Viral cause most common; varies by region
Primary cause	Autoimmune (post-GAS)	Atherosclerosis	Sarcomeric gene mutation	Virus, parasite, autoimmune, drugs
Genetic basis	HLA class II, IGH locus; multigenic susceptibility	>160 GWAS loci; FH in monogenic cases	Autosomal dominant sarcomeric mutations (MYH7, MYBPC3, TNNT2)	HLA modifies susceptibility; not primarily genetic
Key pathogenesis	Molecular mimicry → valvular inflammation	Plaque rupture → thrombosis → ischaemia	Gain-of-function sarcomere → diastolic dysfunction + LVOT obstruction	Viral cytolysis → immune injury → fibrosis → DCM
Primary cardiac lesion	Mitral valve damage (regurgitation → stenosis)	Myocardial infarction / ischaemia	Asymmetric septal hypertrophy; diastolic dysfunction	Myocyte necrosis; inflammatory infiltrate
Clinical hallmark	Mitral stenosis murmur; AF; heart failure	Angina; ACS; HFrEF	Exertional syncope; systolic ejection murmur (dynamic)	Chest pain; pericarditis; new heart failure in young patient
SCD risk	Moderate (AF, embolism)	High (especially first 48h post-MI)	High in young (most common cause in athletes)	Moderate (arrhythmias, giant cell)
Course	Progressive over decades; recurrence worsens valves	Depends on LV function and residual ischaemia	Variable; SCD risk highest in young; ~5-10% develop DCM	Usually self-limited; ~10-30% → DCM

Key References:

Harrison's Principles of Internal Medicine 22E (2025), Chapter 371 (Rheumatic Fever and RHD), pp. 2897-2902
Braunwald's Heart Disease, 2-Vol Set (Chapter 55, Myocarditis), pp. 699-735
Robbins & Kumar Basic Pathology (Cardiomyopathy/Myocarditis chapter), pp. 370-376
Goldman-Cecil Medicine (Rheumatic Valvular Heart Disease; Aortic Stenosis chapters), pp. 608-640

This is a shared conversation. Sign in to Orris to start your own chat.